Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.70 +0.16 (+0.65%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
From Pfizer Inc.
Via Business Wire
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
Via The Motley Fool
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald... 
Via Benzinga
Topics Government
Exposures Political
Can This Beaten-Down Stock Bounce Back in 2025?
Via The Motley Fool
Pfizer Unusual Options Activity For January 21
Via Benzinga
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo improved response rates and duration in BRAF V600E-mutant metastatic colorectal cancer. 
Via Benzinga
What's Going On With Pfizer Stock Monday?
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's decision to not pursue a proxy battle with the company. 
Via Benzinga
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For Now
Pfizer made a promising move Monday after the deadline passed for Starboard to nominate board members. 
Via Investor's Business Daily
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
JD Vance: 'Prices Are Going To Come Down, But It's Going To Take Time,' As Trump's Energy Policies Start To Take Effect
U.S. Vice President JD Vance acknowledged Sunday that Americans will need to wait before seeing relief from high grocery prices, despite the President Donald Trump administration's flurry of executive... 
Via Benzinga
Topics Government
Exposures Political
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Have $500? 2 High-Yield Dividend Stocks to Buy Right Now
Via The Motley Fool
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Is It Safe To Buy These High-Yielding S&P 500 Stocks?
The S&P 500 index has done well over the years. Companies like Walgreens, Pfizer, and Ford are high-yielding. Other high-yielding S&P 500 index stocks are Altria and Franklin Resources. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Got $100? This Top Dividend ETF Is a No-Brainer Buy Right Now.
Via The Motley Fool
Topics ETFs
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Exposures COVID-19
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy? 
Via MarketBeat
Exposures COVID-19 Product Safety
Is Pfizer Stock a Buy?
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light. 
Via The Motley Fool
Exposures COVID-19
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
Medical marijuana reduces benzodiazepine prescriptions, saving patients from potential risks. This threatens big pharma's profits. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
Via The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
3 Subtle Investing Mistakes I Won't Repeat in 2025 And Beyond
Via The Motley Fool
Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,000 in Passive Income in 2025
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $100 Right Now
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.